The goal of this clinical trial is to clarify the interaction of central insulin action and physical activity with the immune system. Therefore, participants will undergo bicycle spiroergometer tests. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray. In another trial (NCT06552130) lean participants already have been tested. Significant effects on circulating cytokines could be identified. In this amendment, overweight persons in which brain insulin resistance is expected will be tested.
BMI > 28 kg/m2
no known primary disease
hormonal contraception with a single-phase preparation
alcohol or drug abuse
At screening: Hb < 12 g/dl for women and Hb < 14 g/dl for men
Any (clinical) condition that would endanger participant's safety or question scientific success according to a physician's opinion.